<DOC>
	<DOCNO>NCT01981668</DOCNO>
	<brief_summary>This study utilize conventional phase I study design ' 3+3 cohort expansion ' design ( 15 ) , determine maximum tolerate dose ( MTD ) 1 ) Cabazitaxel , Part A , 2 ) Radiotherapy , Part B . The determination MTD give Section 5.2 , Definition Dose - Limiting Toxicity . All patient enter study , begin concurrent chemo-radiation analyzable primary endpoint study .</brief_summary>
	<brief_title>The JET Study : Phase I Trial Cabazitaxel , Radiotherapy Long-term Androgen Deprivation</brief_title>
	<detailed_description>This study utilize conventional phase I study design ' 3+3 cohort expansion ' design ( 15 ) , determine maximum tolerate dose ( MTD ) 1 ) Cabazitaxel , Part A , 2 ) Radiotherapy , Part B . The determination MTD give Section 5.2 , Definition Dose - Limiting Toxicity . All patient enter study , begin concurrent chemo-radiation analyzable primary endpoint study . Assuming dose-limiting toxicity encounter , maximum dose Cabazitaxel reach , Part A study , maximum dose Radiotherapy reach Part B study , maximum number patient required follow : Clinical Study Protocol - The JET study Date : September 11 , 2012 Part A : 3 patient per level x 5 level , plus 3 patient ( total 6 ) high dose level Cabazitaxel = 15 + 3 = 18 Part B : 3 patient per level x 3 level , plus 3 patient ( total 6 ) high dose level Radiotherapy = 9 + 3 = 12 The total number patient require 30 . Patients complete concurrent chemotherapy , radiotherapy , androgen deprivation therapy , reason DLT replace . Given experience chemo-radiation study similar patient population , Centre anticipate accrue 3 patient per month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>High risk prostate cancer mets</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>